Skip to content
10-K

Annual Report

ACCENTIA BIOPHARMACEUTICALS INC

0001193125-12-514944

← back to feed
Filed
Dec 26, 2012 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2012 · Nov 30, 2012 89.76M sh
Capex FY 2012 · Sep 30, 2012 $98K
Capex FY 2012 · Sep 30, 2011 $789.07K
Operating Cash Flow FY 2012 · Sep 30, 2012 −$6.31M
Operating Cash Flow FY 2012 · Sep 30, 2011 −$6.12M
Long Term Debt FY 2012 · Sep 30, 2012 $23.65M
Cash And Equivalents FY 2012 · Sep 30, 2012 $129.17K
Cash And Equivalents FY 2012 · Sep 30, 2011 $420.54K
Cash And Equivalents FY 2012 · Sep 30, 2010 $558.45K
Stockholders Equity FY 2012 · Sep 30, 2012 −$63.13M
Stockholders Equity FY 2012 · Sep 30, 2011 −$74.56M
Current Liabilities FY 2012 · Sep 30, 2012 $55.96M
Current Liabilities FY 2012 · Sep 30, 2011 $31.27M
Total Liabilities FY 2012 · Sep 30, 2012 $82.32M
Total Liabilities FY 2012 · Sep 30, 2011 $92.97M
Current Assets FY 2012 · Sep 30, 2012 $1M
Current Assets FY 2012 · Sep 30, 2011 $2.87M
Total Assets FY 2012 · Sep 30, 2012 $2.58M
Total Assets FY 2012 · Sep 30, 2011 $5.91M
Sga Expense FY 2012 · Sep 30, 2012 $7.41M
Sga Expense FY 2012 · Sep 30, 2011 $20.25M
Rd Expense FY 2012 · Sep 30, 2012 $5.24M
Rd Expense FY 2012 · Sep 30, 2011 $2.23M
Operating Income FY 2012 · Sep 30, 2012 −$11.54M
Operating Income FY 2012 · Sep 30, 2011 −$21.17M
Gross Profit FY 2012 · Sep 30, 2012 $1.28M
Gross Profit FY 2012 · Sep 30, 2011 $1.47M
Cost Of Revenue FY 2012 · Sep 30, 2012 $2.77M
Cost Of Revenue FY 2012 · Sep 30, 2011 $2.49M
Revenue FY 2012 · Sep 30, 2012 $4.05M
Revenue FY 2012 · Sep 30, 2011 $3.96M